ProCE Banner Activity

Insights From the Field: Expert Commentary on ADA 2024 Highlights

Clinical Thought

In this commentary, I invite you to explore the key findings from the FLOW, CATALYST, and TIGHT studies presented at ADA 2024. Join me as I delve into the implications of these recent trials and discuss how they can enhance our treatment strategies in diabetes care.

Released: October 10, 2024

Expiration: October 09, 2025

Share

Faculty

Martin J. Abrahamson

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and and ProCE, LLC

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company; and Abbott Diabetes Care Inc.

Abbott Diabetes Care Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Partners

Practicing Clinicians Exchange

ProCE Banner

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson, MD, FACP, has no relevant financial relationships to disclose.